絞り込み

16645

広告

Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.

著者 Wu J , Chen Y , Hageman L , Francisco L , Ness EC , Parman M , Kung M , Watson JA , Weisdorf DJ , Snyder DS , McGlave PB , Forman SJ , Arora M , Armenian SH , Bhatia R , Bhatia S
Cancer.2019 Aug 14 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 0users)

Full Text Sources

Late mortality was investigated in patients with chronic myelogenous leukemia (CML) who underwent blood or bone marrow transplant (BMT) with or without prior tyrosine kinase inhibitor (TKI) therapy.
PMID: 31412155 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード